Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Nifedipine.
Nifedipine is in a class of medications called calcium-channel blockers in the dihydropyridine subclass. Nifedipine is used as an antihypertensive and as an anti-anginal medication. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood and oxygen to the heart.
The CEP showcases our expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 879.90 as compared to the previous close of Rs. 863.40. The total number of shares traded during the day was 42509 in over 2373 trades.
The stock hit an intraday high of Rs. 917.20 and intraday low of 874.05. The net turnover during the day was Rs. 38019239.00. |
